Section 132: Advanced Systems Immunology and Network Pharmacology in CBS/PSP

Migration, Crosslink

📖

Section 132: Advanced Systems Immunology and Network Pharmacology in CBS/PSP

active

wiki page Created: 2026-04-02T07:18:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-section-132-systems-im

📖 Wiki Page

therapeutic2920 wordssynced 2026-04-02

Section 132: Advanced Systems Immunology and Network Pharmacology in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 132: Advanced Systems Immunology and Network Pharmacology in CBS/PSP</th>
</tr>
<tr>
<td class="label">Name</td>
<td>Section 132: Advanced Systems Immunology and Network Pharmacology in CBS/PSP</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

The treatment of corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) has historically relied on single-target pharmacological interventions that fail to address the complex, multi-factorial nature of these neurodegenerative disorders. Systems immunology and network pharmacology represent a paradigm shift in therapeutic approach, recognizing that these conditions involve dysregulation across multiple interconnected biological networks rather than single molecular targets[@hopkins2008].

...

Section 132: Advanced Systems Immunology and Network Pharmacology in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 132: Advanced Systems Immunology and Network Pharmacology in CBS/PSP</th>
</tr>
<tr>
<td class="label">Name</td>
<td>Section 132: Advanced Systems Immunology and Network Pharmacology in CBS/PSP</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

The treatment of corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) has historically relied on single-target pharmacological interventions that fail to address the complex, multi-factorial nature of these neurodegenerative disorders. Systems immunology and network pharmacology represent a paradigm shift in therapeutic approach, recognizing that these conditions involve dysregulation across multiple interconnected biological networks rather than single molecular targets[@hopkins2008].

This section provides comprehensive coverage of advanced computational and systems-based approaches to therapy development for CBS and PSP. These include network pharmacology analysis for identifying multi-target drug candidates, systems biology models of neuroinflammation, cytokine network modulation strategies, immune cell phenotyping approaches, biomarker-guided immunomodulation, computational drug repurposing pipelines, and patient-specific immune profiling methodologies. Together, these approaches offer the potential to develop more effective, personalized treatment strategies that address the underlying pathophysiology of these conditions rather than merely treating symptoms[@menche2015].

1. Network Pharmacology in CBS/PSP

1.1 Principles of Network Pharmacology

Network pharmacology represents a fundamental shift from the traditional "one gene, one drug, one disease" paradigm to a network-based understanding of drug action[@csermely2013]. This approach recognizes that drugs modulate multiple targets within interconnected biological networks, and that therapeutic efficacy often arises from the collective modulation of disease-relevant network modules rather than single target engagement.

Core Principles:

Network Perturbation Theory: Diseases arise from perturbations in biological networks, and effective treatments must restore network equilibrium. In CBS and PSP, the tauopathy network involves interconnected pathways including microtubule stabilization, protein aggregation, neuroinflammation, and cellular stress responses.

Polypharmacology: Many effective drugs exhibit activity at multiple targets. Network pharmacology embraces this property, seeking drugs or drug combinations that optimally modulate disease-relevant networks rather than single targets.

Network Robustness and Fragility: Biological networks exhibit robustness against random perturbations but may have specific vulnerabilities (essential nodes) that can be targeted therapeutically. Computational analysis can identify these fragile points in disease networks.

1.2 Constructing Disease-Specific Networks

Network pharmacology analysis for CBS and PSP begins with the construction of disease-specific networks incorporating multiple data types:

Protein-Protein Interaction (PPI) Networks:

Curated from databases including STRING, BioGRID, and IntAct
Include physical and functional interactions
Filtered for brain-specific interactions where possible

Signal Transduction Networks:

Receptor-ligand relationships
Kinase-substrate relationships
Transcription factor-target relationships

Gene Regulatory Networks:

Transcriptional regulation
Post-transcriptional regulation (miRNA, lncRNA)
Epigenetic regulation

Disease-Specific Network Assembly:

Genes associated with CBS/PSP from GWAS, exome sequencing, and candidate gene studies
Proteins interacting with known disease proteins
Pathways enriched in disease tissue Transcriptomics

1.3 Target Identification and Drug Screening

Network-Based Target Identification:

Network propagation algorithms identify disease-associated genes within PPI networks by:

Seeding the network with known disease genes

Allowing signal to propagate through network edges

Ranking genes by their proximity to seed nodes

Prioritizing genes with high propagation scores as novel targets

Drug-Target Interaction Prediction:

Computational approaches for predicting drug-target interactions include:

Molecular docking simulations
Machine learning models trained on known drug-target pairs
Network-based inference methods
Ligand-based similarity approaches

Multi-Target Drug Optimization:

Once candidate targets are identified, network pharmacology seeks drugs or combinations that:

Maximize engagement of disease-related targets
Minimize engagement of targets associated with adverse effects
Achieve optimal network perturbation profiles

1.4 Applications to CBS/PSP

Tauopathy Network Analysis:

The tauopathy network in CBS and PSP involves multiple interconnected pathways:

Microtubule dynamics and tau phosphorylation
Protein quality control systems (UPS, autophagy)
Mitochondrial function and energy metabolism
Neuroinflammation and immune response
Synaptic function and plasticity

Network analysis has identified several key nodes within this network that represent promising therapeutic targets:

GSK3B (glycogen synthase kinase 3 beta): Central kinase in tau phosphorylation
CDK5 (cyclin-dependent kinase 5): Regulatory kinase in tau pathology
PP2A (protein phosphatase 2A): Major tau phosphatase
HSP90: Molecular chaperone involved in tau clearance

Network-Derived Drug Candidates:

Several existing drugs have been identified as network-based candidates for CBS/PSP through network pharmacology approaches:

Lithium: Multiple network effects including GSK3B inhibition
Rapamycin: mTOR inhibition and autophagy enhancement
Metformin: AMPK activation and metabolic effects
Minocycline: Anti-inflammatory and neuroprotective effects

2. Multi-Target Drug Combinations

2.1 Rationale for Combination Therapy

Single-target drugs often fail in complex neurodegenerative diseases because:

Redundant pathways compensate for target blockade
Disease heterogeneity requires individualized targeting
Single targets may be insufficient to modify disease course

Multi-target drug combinations offer several advantages:

Simultaneous modulation of multiple disease pathways
Lower doses of individual drugs may achieve efficacy with reduced toxicity
Potential synergistic effects that exceed additive predictions
Ability to address disease heterogeneity through personalized combinations

2.2 Combination Optimization Strategies

Network-Based Combination Design:

Target Coverage Analysis: Map disease network to identify key pathways requiring modulation

Drug Profiling: Characterize known drugs for their network effects (target profiles, network perturbations)

Combination Search: Systematic evaluation of drug combinations for optimal network coverage

Synergy Detection: Identify combinations with synergistic rather than merely additive effects

Key Parameters for Optimization:

Coverage of disease-relevant network nodes
Minimization of off-target effects
Pharmacokinetic compatibility
Safety profile compatibility

2.3 Approved Drug Combinations

Existing Combinatorial Approaches:

Several drug combinations have been explored or are in development for CBS/PSP:

Levodopa Plus Adjunctive Therapy:

Carbidopa/levodopa combined with entacapone
Extended-release formulations
Novel adjuncts targeting non-dopaminergic pathways

Anti-Tau Combination Strategies:

Tau phosphorylation inhibitors (lithium, GSK3B inhibitors) plus aggregation inhibitors
Anti-tau antibodies combined with small molecules
Combination targeting different tau species (oligomers, fibrils, phosphorylated forms)

Neuroinflammation Modulation Combinations:

GLP-1 receptor agonists with anti-inflammatory agents
Cytokine-targeting biologics combined with small molecule immunomodulators

2.4 Computational Combination Design

Network Influence Models:

Computational models predict combination effects by:

Simulating drug effects on disease networks
Calculating network perturbation scores
Predicting combination synergy using machine learning
Validating predictions against known combination data

Clinical Translation:

Computational approaches to combination design translate to clinical practice through:

Identified combinations tested in early-phase clinical trials
Biomarker development for monitoring combination effects
Patient stratification based on network analysis
Dose optimization for combination regimens

3. Systems Biology of Neuroinflammation

3.1 Neuroinflammation in CBS/PSP

Neuroinflammation is a central pathological feature of both CBS and PSP, characterized by:

Activated microglia in affected brain regions
Elevated pro-inflammatory cytokines in brain tissue and cerebrospinal fluid
Reactive astrocytes contributing to neurotoxicity
Peripheral immune system involvement

Key Inflammatory Pathways:

Toll-like receptor (TLR) signaling
NLRP3 inflammasome activation
NF-κB-mediated cytokine production
Complement system activation

3.2 Systems Immunology Approaches

Multi-Level Modeling:

Systems biology approaches model neuroinflammation across multiple levels:

Molecular Level:

Cytokine signaling networks
Receptor activation cascades
Transcription factor networks
Epigenetic modifications

Cellular Level:

Microglial activation states
Astrocyte reactivity
T cell infiltration and activation
Peripheral immune cell trafficking

Tissue Level:

Spatial distribution of inflammation
Brain region-specific effects
Blood-brain barrier integrity

3.3 Computational Models of Neuroinflammation

Ordinary Differential Equation (ODE) Models:

Quantify cytokine production and consumption rates
Model cell population dynamics
Predict temporal evolution of inflammation
Optimize intervention timing

Agent-Based Models:

Simulate individual cell behaviors
Capture spatial heterogeneity
Model cell-cell interactions
Predict emergent population-level effects

Boolean Network Models:

Capture qualitative dynamics of signaling networks
Identify stable states (homeostatic, inflammatory)
Predict system responses to perturbations

3.4 Therapeutic Implications

Systems biology of neuroinflammation informs therapy through:

Identification of key intervention points
Prediction of intervention effects across the network
Optimization of combination approaches
Patient stratification based on inflammatory profiles

4. Cytokine Network Modulation

4.1 Cytokine Networks in CBS/PSP

The cytokine network in CBS and PSP involves multiple interacting signaling molecules:

Pro-Inflammatory Cytokines:

IL-1β: Central mediator of neuroinflammation
IL-6: Pleiotropic cytokine with inflammatory and regenerative functions
TNF-α: Potent pro-inflammatory mediator
IFN-γ: Type II interferon with immunomodulatory effects

Anti-Inflammatory Cytokines:

IL-10: Broad anti-inflammatory effects
TGF-β: Immunoregulatory and tissue repair functions
IL-1RA: IL-1 receptor antagonist

Modulatory Cytokines:

IL-4, IL-13: Th2 polarization
IL-17: Th17-related inflammation

4.2 Network Properties

Cytokine Network Characteristics:

The cytokine network exhibits several key properties:

Redundancy: Multiple cytokines can trigger similar responses
Pleiotropy: Individual cytokines have multiple effects
Cascades: Cytokines can trigger production of other cytokines
Feedback loops: Both positive and negative feedback regulate responses

Network Topology Analysis:

Central nodes: IL-1β, TNF-α, IL-6
Signal amplifiers: IL-1β, TNF-α
Negative regulators: IL-10, TGF-β, IL-1RA

4.3 Modulation Strategies

Cytokine Targeting Approaches:

Neutralization:

Monoclonal antibodies against specific cytokines
Soluble receptor constructs
Receptor-Fc fusion proteins

Receptor Modulation:

Receptor antagonists
Downstream signaling inhibitors
Receptor internalization enhancers

Production Inhibition:

NF-κB inhibitors
NLRP3 inflammasome blockers
Caspase-1 inhibitors

4.4 Clinical Applications

Biologic Therapies:

Several cytokine-targeting biologics have been or are being evaluated:

Tocilizumab: IL-6 receptor antagonist (clinical trials in AD)
Canakinumab: IL-1β neutralizing antibody (cardiovascular outcomes trial)
Anakinra: IL-1 receptor antagonist
Etanercept: TNF-α receptor fusion protein

Small Molecule Approaches:

NLRP3 inhibitors
JAK inhibitors for cytokine signaling
PDE inhibitors affecting inflammatory pathways

5. Immune Cell Phenotyping

5.1 Immune Cell Populations in CBS/PSP

Central Nervous System Immune Cells:

Microglia:

Resting (surveillance) state
M1 (classically activated) state
M2 (alternatively activated) state
Disease-associated microglia (DAM)
Age-associated microglia

Astrocytes:

A1 (neurotoxic) phenotype
A2 (neuroprotective) phenotype

Peripheral Immune Cells:

T lymphocytes (CD4+, CD8+, regulatory T cells)
B lymphocytes
Monocytes/macrophages
Natural killer cells

5.2 Phenotyping Methodologies

Flow Cytometry:

Surface marker analysis
Intracellular cytokine staining
Functional assays
Single-cell profiling

Single-Cell RNA Sequencing:

Transcriptomic profiling at single-cell resolution
Identification of novel cell states
Trajectory analysis
Cell-cell communication inference

Mass Cytometry (CyTOF):

High-dimensional phenotyping
Simultaneous measurement of multiple parameters
Minimal spectral overlap
Single-cell resolution

5.3 Biomarker Discovery

Cellular Biomarkers:

Immune cell phenotyping identifies biomarkers for:

Disease diagnosis
Progression monitoring
Treatment response prediction
Patient stratification

Emerging Biomarkers:

TREM2 expression on microglia
CD163+ monocyte subsets
Regulatory T cell ratios
Cytokine-producing T cell profiles

5.4 Clinical Applications

Diagnostic Applications:

Differential diagnosis of parkinsonian syndromes
Disease subtype identification
Early detection of progression

Therapeutic Monitoring:

Treatment response tracking
Adverse effect prediction
Dose optimization guidance

6. Biomarker-Guided Immunomodulation

6.1 Biomarker Categories

Fluid Biomarkers:

Cerebrospinal Fluid (CSF):

Cytokine levels (IL-1β, IL-6, TNF-α, IL-10)
Neurofilament light chain (NfL)
Total tau and phosphorylated tau
β-amyloid species

Blood-Based Biomarkers:

Peripheral cytokine levels
Immune cell activation markers
Extracellular vesicles
Exosomal cargo

Imaging Biomarkers:

TSPO PET for microglial activation
CSF ROA-PET for neuroinflammation
MR spectroscopy for metabolic changes

6.2 Biomarker-Driven Therapy

Personalized Immunomodulation:

Biomarker guidance enables:

Patient selection for specific immunomodulatory therapies
Dose optimization based on biomarker levels
Treatment response monitoring
Adaptive therapy adjustments

Trial Designs:

Biomarker-enriched clinical trials
Adaptive designs with biomarker-based modification
N-of-1 trials for individualized therapy

6.3 Implementation Challenges

Technical Challenges:

Assay standardization
Biomarker validation
Longitudinal stability
Cost and accessibility

Biological Challenges:

Disease heterogeneity
Biomarker-disease relationships
Placebo effects
Sample size requirements

7. Computational Approaches for Drug Repurposing

7.1 Drug Repurposing Pipeline

Stages of Repurposing:

Stage 1: Target Identification

Disease network construction
Key node identification
Prioritization of targets

Stage 2: Drug Screening

Drug-target interaction prediction
Network effect estimation
Prioritization of candidate drugs

Stage 3: Validation

In vitro screening
Animal model testing
Clinical proof-of-concept

Stage 4: Clinical Development

Regulatory pathway planning
Trial design
Commercialization

7.2 Computational Methods

Machine Learning Approaches:

Supervised Learning:

Train models on known drug-disease pairs
Predict repurposing candidates
Feature engineering from molecular data

Unsupervised Learning:

Drug similarity clustering
Disease similarity mapping
Novel association detection

Network-Based Methods:

Network Propagation:

Disease gene propagation in PPI networks
Drug effect propagation
Association scoring

Network Embedding:

Node2vec and related methods
Graph neural networks
Knowledge graph embeddings

7.3 Repurposing Databases

Key Resources:

DrugBank: Drug information and targets
CTD: Comparative toxicogenomics
LINCS: Library of integrated network-based cellular signatures
Repurposing Hub (Broad Institute)

7.4 CBS/PSP-Specific Repurposing

Prioritized Candidates:

Computational repurposing has identified several candidates for CBS/PSP:

Lithium: Multiple effects on tau pathology, neuroinflammation
Metformin: Metabolic effects, autophagy enhancement
Minocycline: Anti-inflammatory, neuroprotective
Statins: Immunomodulatory effects
GLP-1 agonists: Anti-inflammatory, neuroprotective

8. Patient-Specific Immune Profiling

8.1 Rationale for Personalization

Disease Heterogeneity:

CBS and PSP exhibit significant clinical and pathological heterogeneity:

Multiple clinical phenotypes
Variable tau pathology distribution
Different rates of progression
Variable treatment responses

Immune System Variation:

Patient immune profiles differ based on:

Genetic background
Age and comorbidities
Medication history
Lifestyle factors

8.2 Profiling Technologies

Multi-Omics Integration:

Genomics:

HLA typing for immune response prediction
Immune-related genetic variants
Pharmacogenomic markers

Transcriptomics:

Blood immune cell transcriptomes
CSF cell transcriptomes
Single-cell RNA-seq

Proteomics:

Cytokine profiling
Antibody profiling
Surface marker analysis

Metabolomics:

Metabolic state indicators
Biomarker discovery
Treatment response prediction

8.3 Clinical Implementation

Framework for Personalization:

Baseline Profiling

Comprehensive immune assessment
Genetic screening
Biomarker measurement

Treatment Selection

Match patient profile to therapy
Consider contraindications
Optimize combination approaches

Monitoring and Adjustment

Serial biomarker measurement
Clinical response tracking
Adaptive therapy modification

8.4 Challenges and Future Directions

Current Limitations:

Cost and accessibility of comprehensive profiling
Data integration complexity
Validation of biomarkers
Clinical utility demonstration

Future Directions:

Point-of-care immune monitoring
Real-time data integration
AI-driven treatment recommendations
Closed-loop therapy systems

9. Integration and Future Directions

9.1 Convergent Therapeutic Strategies

The approaches described in this section converge on several key therapeutic strategies for CBS and PSP:

Network-Level Intervention:

Multi-target drug combinations
Systems-based treatment optimization
Network modulation rather than single-target blockade

Immunomodulation:

Rational cytokine network modulation
Biomarker-guided immunotherapy
Patient-specific immune profiling

Personalized Medicine:

Individual patient network analysis
Treatment matching based on molecular profiles
Adaptive therapy based on monitoring

9.2 Emerging Technologies

Single-Cell Technologies:

Enhanced immune cell profiling
Spatial transcriptomics
Multi-omic integration

Computational Advances:

Deep learning for drug-target prediction
Digital twins for patient modeling
Causal inference methods

Therapeutic Innovations:

Gene therapy approaches
Cell therapy combinations
Novel biologic modalities

9.3 Research Priorities

Near-Term Priorities:

Validation of network pharmacology predictions
Biomarker qualification for clinical use
Combination therapy optimization

Long-Term Vision:

Integrated systems immunology platform
Precision medicine for CBS/PSP
Disease-modifying therapies based on network understanding

10. Conclusion

Systems immunology and network pharmacology represent transformative approaches to developing effective therapies for CBS and PSP. These methods recognize the inherent complexity of neurodegenerative disease and provide frameworks for addressing that complexity through multi-target interventions, computational modeling, and personalized treatment strategies.

The integration of network-based drug discovery, immune profiling, biomarker-guided therapy, and computational repurposing creates a comprehensive pipeline for developing disease-modifying treatments. While significant challenges remain, particularly in validation and clinical implementation, the foundation is being built for a new generation of therapies that target the underlying pathophysiology of CBS and PSP rather than merely alleviating symptoms.

As computational capabilities improve and biological understanding deepens, these approaches will become increasingly central to drug development for neurodegenerative diseases. The ultimate goal—personalized, network-informed therapy that modifies disease course—moves closer to realization through the continued development and integration of the methods described in this section.

References

[Unknown, Hopkins, A. L. (2008). Network pharmacology: the next paradigm in drug discovery (2008)](https://doi.org/10.1038/nchembio.118)

[Menche, M., et al, (2015) (2015)](https://doi.org/10.1126/science.1257601)

[Csermely, P., et al, (2013) (2013)](https://doi.org/10.1146/annurev-biochem-060111-122444)

[Litvan, C. G., et al., (2012). Current concepts: Corticobasal degeneration (2012)](https://doi.org/10.1016/S1474-4422(02)

[Boxer, A. L., et al., (2013). Advances in progressive supranuclear palsy: New diagnostic criteria, biomarkers, and therapeutic approaches (2013)](https://doi.org/10.1016/S1474-4422(13)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — 0.65 · Target: PIEZO1 and KCNK2
[Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — 0.57 · Target: DGAT1 and SOAT1
[TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — 0.55 · Target: TREM2
[Synthetic Biology Approach: Designer Mitochondrial Export Systems](/hypothesis/h-495454ef) — 0.51 · Target: Synthetic fusion proteins
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — 0.58 · Target: TREM2
[TREM2-Dependent Microglial Senescence Transition](/hypothesis/h-61196ade) — 0.76 · Target: TREM2

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Mitochondrial transfer between neurons and glia](/analysis/SDA-2026-04-01-gap-20260401231108) 🔄
[Protein aggregation cross-seeding across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-9137255b) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-section-132-systems-immunology-network-pharmacology-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-section-132-systems-immunology-network-pharmacology-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-12a836f6f480
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-132-systems-immunology-network-pharmacology-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

319

Outgoing

341

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Section 132: Advanced Systems Immunology and Network Pharmacology in CBS/PSP

Section 132: Advanced Systems Immunology and Network Pharmacology in CBS/PSP

Overview

Section 132: Advanced Systems Immunology and Network Pharmacology in CBS/PSP

Overview

1. Network Pharmacology in CBS/PSP

1.1 Principles of Network Pharmacology

1.2 Constructing Disease-Specific Networks

1.3 Target Identification and Drug Screening

1.4 Applications to CBS/PSP

2. Multi-Target Drug Combinations

2.1 Rationale for Combination Therapy

2.2 Combination Optimization Strategies

2.3 Approved Drug Combinations

2.4 Computational Combination Design

3. Systems Biology of Neuroinflammation

3.1 Neuroinflammation in CBS/PSP

3.2 Systems Immunology Approaches

3.3 Computational Models of Neuroinflammation

3.4 Therapeutic Implications

4. Cytokine Network Modulation

4.1 Cytokine Networks in CBS/PSP

4.2 Network Properties

4.3 Modulation Strategies

4.4 Clinical Applications

5. Immune Cell Phenotyping

5.1 Immune Cell Populations in CBS/PSP

5.2 Phenotyping Methodologies

5.3 Biomarker Discovery

5.4 Clinical Applications

6. Biomarker-Guided Immunomodulation

6.1 Biomarker Categories

6.2 Biomarker-Driven Therapy

6.3 Implementation Challenges

7. Computational Approaches for Drug Repurposing

7.1 Drug Repurposing Pipeline

7.2 Computational Methods

7.3 Repurposing Databases

7.4 CBS/PSP-Specific Repurposing

8. Patient-Specific Immune Profiling

8.1 Rationale for Personalization

8.2 Profiling Technologies

8.3 Clinical Implementation

8.4 Challenges and Future Directions

9. Integration and Future Directions

9.1 Convergent Therapeutic Strategies

9.2 Emerging Technologies

9.3 Research Priorities

10. Conclusion

References

Related Hypotheses

💬 Discussion